Brooklyn ImmunoTherapeutics is a clinical stage biopharmaceutical company that is focused on exploring the role that cytokine-based therapies can have in treating patients with cancer, both as a single agent and in combination with other anti-cancer treatments.
The company's leading product candidate is IRX-2, a cytokine based therapy. It delivers IL-2 and other key cytokines to potentially restore immune function in the tumor microenvironment, thereby enabling the immune system to attack cancer cells. In a Phase 2A clinical trial, IRX-2 demonstrated an increase in tumor infiltrating lymphocytes, which is associated with a survival benefit in patients with head and neck cancer. Brooklyn ImmunoTherapeutics has initiated a Phase 2B clinical study of IRX-2 in patients with squamous cell cancer of the head and neck, with results expected to be reported in 2020.
The company is also exploring the potential of IRX-2 in other oncology indications in collaboration with multiple pharmaceutical companies. Clinical trials in combination with other anti-cancer agents such as checkpoint inhibitors are also being conducted.
Lynn Sadowski Mason
VP, Clinical Operations
Senior Technical Advisor
Senior VP, Regulatory Affairs and Quality Systems
Brooklyn ImmunoTherapeutics Acquires IRX Therapeutics
Brooklyn ImmunoTherapeutics Announces Presentation of Positive Results of IRX-2 Therapy in Resectable Breast Cancer and Head and Neck Cancer at the 33rd Annual Meeting of the Society for Immunotherapy of Cancer
Documentaries, videos and podcasts
- CytokineBroad and loose category of small proteins (~5–20 kda) that are important in cell signaling
- BiotechnologyBiotechnology can refer to the application of science and technology to living organisms or the use of living organisms, their parts, products or models thereof to solve a problem, produce knowledge or produce goods and services. Biotechnology may involve the alteration of living or non-living materials.